Stockscreener 앱 받기
0.0235
38.24%
0.0065
시간 외 거래:
.02
-0.0035
-14.89%
전일 마감가:
$0.017
열려 있는:
$0.024
하루 거래량:
7,240
Relative Volume:
6.30
시가총액:
$N/A
수익:
-
순이익/손실:
$-69.68M
주가수익비율:
-0.0124
EPS:
-1.89
순현금흐름:
$-48.93M
1주 성능:
+38.24%
1개월 성능:
+38.24%
6개월 성능:
-23.49%
1년 성능:
-96.95%
1일 변동 폭
$0.0235
$0.026
1주일 범위
$0.0235
$0.026
52주 변동 폭
$0.017
$0.026
갈레라 테라 Stock (GRTX) Company Profile
GRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0235 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
갈레라 테라 Stock (GRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-19 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2019-12-02 | 개시 | BTIG Research | Buy |
| 2019-12-02 | 개시 | BofA/Merrill | Buy |
| 2019-12-02 | 개시 | Citigroup | Buy |
| 2019-12-02 | 개시 | Credit Suisse | Neutral |
모두보기
갈레라 테라 주식(GRTX)의 최신 뉴스
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Radiation-Induced Oral Mucositis in Head and Neck Cancer Market is expected to reach USD 1.63 billion by 2034 - openPR.com
North American Morning Briefing : Stock Futures -2- - MarketScreener
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H - ScienceDirect.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance
Mark Bachleda takes the helm at Eyconis - biocentury.com
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia
갈레라 테라 (GRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):